The clinical-stage biopharmaceutical company should soon be closer to potentially launching its first product.Shares of Viking Therapeutics (VKTX 34.18%) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the clinical-stage biopharmaceutical company provided its second-quarter update following the market close on Wednesday.Viking reported no revenue and a net loss of $22.3 million, or$0.20 per share, in Q2. However, the company's financial results weren't the big story in the ...